Mind Medicine (MindMed) Inc. MNMD · Stock Open Mind Medicine (MindMed) Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Mind Medicine (MindMed) Inc. Analysis (MNMD)
Is Mind Medicine (MindMed) Inc. a good investment? Mind Medicine (MindMed) Inc. (MNMD) is currently trading at 20.69 USD. Market analysts have a consensus price target of 28.67 USD. This suggests a potential upside from current levels.
Earnings Schedule: Mind Medicine (MindMed) Inc. is expected to release its next earnings report on May 7, 2026. The market consensus estimate for Forward EPS is -1.77.
Investor FAQ
Does Mind Medicine (MindMed) Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Mind Medicine (MindMed) Inc.?
Mind Medicine (MindMed) Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be May 7, 2026. The company currently has a trailing EPS of -1.98.
Company Profile
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
| Split Date | Split Ratio to 1 |
|---|---|
| Aug. 29, 2022 | 0.07 |
Community Discussion